We have recently reported that a panel autoantibody against six TAAs (p53, NY-ESO-1, MMP-7, Hsp70, PRDX 6 and Bmi-1) might be used as a blood biomarker-based tool to identify early stage esophageal squamous cell carcinoma (ESCC) and Nasopharyngeal Carcinoma [13, 14]. This evidence concerns the gene TP53 and nasopharyngeal carcinoma.